The effects of gemfibrozil upon the metabolism of chylomicron-like emulsions in patients with endogenous hypertriglyceridemia

Cardiovascular Research

Volumn 49, Issue 2, 2001, Pages 456-465

  Santos, Raul D ^a   Ventura, Laura I ^a   Spósito, Andrei C ^a   Schreiber, Roberto ^a   Ramires, José A F ^a   Maranhão, Raul C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Atherosclerosis; Cholesterol; Computer modelling; Lipid metabolism; Lipoproteins

Indexed keywords

CARBON 14; CHOLESTEROL; CHOLESTEROL OLEATE; CHYLOMICRON; GEMFIBROZIL; PLACEBO; TRIACYLGLYCEROL; TRIOLEIN; TRITIUM;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DRUG CLEARANCE; DRUG EFFECT; EMULSION; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; LIPOLYSIS; MALE; MEAN RESIDENCE TIME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0035253792     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(00)00274-1     Document Type: Article

References (44)

1. Evidence for a common saturable triglyceride removal mechanism for chylomicrons and very low density lipoproteins in man
2. Relationships between the responses of triglyceride-rich lipoproteins in blood plasma containing apolipoproteins B-48 and B-100 to a fat-containing meal in normolipidemic humans
3. Metabolism of triglyceride-rich lipoproteins during alimentary lipemia
4. Chylomicron assembly and catabolism: Role of apolipoproteins and receptors
5. The two-receptor model of lipoprotein clearance: Tests of the hypothesis in 'knockout' mice lacking the low-density lipoprotein receptor, apolipoprotein E, or both proteins
6. Contribution of apo B-48 and apo B-100 triglyceride-rich lipoproteins (TRL) to post-prandial increases in the plasma concentration of TRL triglycerides and retinyl esters
7. Kinetics of chylomicron remnant clearance in normal and in hyperlipoproteinemic subjects
8. Determinants of fasting plasma triglyceride levels: Metabolism of hepatic and intestinal lipoproteins
9. Different patterns of post-prandial lipoprotein metabolism in normal, type IIa, type III, and type IV hyperlipoproteinemic individuals. Effects of treatment with cholestyramine and gemfibrozil
10. Metabolism of protein-free emulsion models of chylomicrons in rats
11. Effects of cholesterol content on the metabolism of protein-free emulsion models of lipoproteins
12. A kinetic model of chylomicron core lipid metabolism in rats: The effect of a single meal
13. Clearance from plasma of triacylglycerol and cholesteryl ester after intravenous injection of chylomicron-like lipid emulsions in rats and man
14. Simultaneous measurements of chylomicron and remnant removal using a doubly labelled artificial lipid emulsion: Studies in normolipidemic and hyperlipidemic subjects
15. Plasma kinetics of a chylomicron-like emulsion in patients with coronary artery disease
16. Transcriptional control of triglycerides metabolism: Fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR
17. Postprandial lipemia, fenofibrate and coronary artery disease
18. Post-prandial metabolism of triglyceride-rich lipoproteins in non-insulin-dependent diabetic patients before and after bezafibrate treatment
19. Prevention of coronary heart disease in clinical practice. Recommendations of the second joint task force of European and other societies on coronary prevention
20. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI
21. 137C transfer rates in marine organisms and dose on man
22. Plasma clearance of chylomicrons labelled with retinyl-palmitate in healthy human subjects
23. Relationship between plasma triglycerides and removal of chylomicrons
24. Chylomicron metabolism in rats: Lipolysis, recirculation of triglyceride derived fatty acids in plasma FFA, and fate of core lipids as analyzed by compartmental modeling
25. Kinetics of chylomicron triglyceride removal from plasma in rats: Effect of dose on the volume of distribution
26. Determinants of post-prandial lipemia in men with coronary artery disease and low levels of HDL cholesterol
27. Apolipoprotein E in hyperlipidemia
28. Interrelationships between insulin secretion and plasma free fatty acid and triglyceride kinetics in maturity onset diabetes and the effect of phenylethylbiguaride (phenphormin)
29. Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man
30. Regulation of hepatic uptake of triglyceride-rich lipoproteins in the rat
31. Effect of gemfibrozil on high density lipoprotein subspecies in non-insulin dependent diabetes mellitus. Relations to lipolytic enzymes and to cholesteryl ester transfer protein activity
32. Upregulation of low density lipoprotein receptor by gemfibrozil, a hypolipidemic agent, in human hepatoma cells through stabilization of mRNA transcripts
33. Gemfibrozil reduces post-prandial lipemia in non-insulin dependent diabetes mellitus
34. Post-prandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease
35. Relation of triglyceride metabolism and coronary artery disease: Studies in post-prandial state
36. Clearance of chylomicron remnants in normolipidemic patients with coronary artery disease: Case control study over 3 years
37. Receptor-mediated uptake of remnant lipoproteins by cholesterol-loaded human monocyte-macrophages
38. Arterial fatty lesions have increased uptake of chylomicron remnants but not low-density lipoproteins
39. High density lipoprotein 2: Relationship of the plasma levels of this lipoprotein species to its composition, to the magnitude of post-prandial lipemia, and to the activities of lipoprotein lipase and hepatic lipase
40. Joint effects of serum triglycerides and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: Implications for treatment
41. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients
42. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol
43. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
44. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease